Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zarxio 15% Price Discount To Neupogen In US Tracks European Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Sandoz's discount to Amgen is not as deep as some expected, but is likely to increase over time.

You may also be interested in...



Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay

US FDA user fee date for privately held company’s 351(k) application referencing Amgen’s Neupogen may have passed without word of a regulatory action; Amgen sued Adello in March alleging infringement of 17 patents covering the innovator product.

Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay

US FDA user fee date for privately held company’s 351(k) application referencing Amgen’s Neupogen may have passed without word of a regulatory action; Amgen sued Adello in March alleging infringement of 17 patents covering the innovator product.

Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017

Zarxio and Basaglar will be the beneficiaries of the cost-cutting move, although how much it will help the follow-on products remains unclear.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel